Literature DB >> 23468190

Cytokine targets in the brain: impact on neurotransmitters and neurocircuits.

Andrew H Miller1, Ebrahim Haroon, Charles L Raison, Jennifer C Felger.   

Abstract

Increasing attention has been paid to the role of inflammation in a host of illnesses including neuropsychiatric disorders such as depression and anxiety. Activation of the inflammatory response leads to release of inflammatory cytokines and mobilization of immune cells both of which have been shown to access the brain and alter behavior. The mechanisms of the effects of inflammation on the brain have become an area of intensive study. Data indicate that cytokines and their signaling pathways including p38 mitogen-activated protein kinase have significant effects on the metabolism of multiple neurotransmitters such as serotonin, dopamine, and glutamate through impact on their synthesis, release, and reuptake. Cytokines also activate the kynurenine pathway, which not only depletes tryptophan, the primary amino acid precursor of serotonin, but also generates neuroactive metabolites that can significantly influence the regulation of dopamine and glutamate. Through their effects on neurotransmitter systems, cytokines impact neurocircuits in the brain including the basal ganglia and anterior cingulate cortex, leading to significant changes in motor activity and motivation as well as anxiety, arousal, and alarm. In the context of environmental challenge from the microbial world, these effects of inflammatory cytokines on the brain represent an orchestrated suite of behavioral and immune responses that subserve evolutionary priorities to shunt metabolic resources away from environmental exploration to fighting infection and wound healing, while also maintaining vigilance against attack, injury, and further pathogen exposure. Chronic activation of this innate behavioral and immune response may lead to depression and anxiety disorders in vulnerable individuals.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23468190      PMCID: PMC4141874          DOI: 10.1002/da.22084

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  101 in total

1.  Oscillations in the basal ganglia.

Authors:  T Wichmann; M R DeLong
Journal:  Nature       Date:  1999-08-12       Impact factor: 49.962

Review 2.  Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness.

Authors:  Shawn Hayley; Zul Merali; Hymie Anisman
Journal:  Stress       Date:  2003-03       Impact factor: 3.493

3.  Cytokine production and treatment response in major depressive disorder.

Authors:  S Lanquillon; J C Krieg; U Bening-Abu-Shach; H Vedder
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

4.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

5.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

6.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

7.  Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.

Authors:  Lucile Capuron; Giuseppe Pagnoni; Marina F Demetrashvili; David H Lawson; Fiona B Fornwalt; Bobbi Woolwine; Gregory S Berns; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

8.  Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier.

Authors:  Tomitsune Kitagami; Kiyofumi Yamada; Hideki Miura; Ryo Hashimoto; Toshitaka Nabeshima; Tatsurou Ohta
Journal:  Brain Res       Date:  2003-07-18       Impact factor: 3.252

9.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

10.  Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.

Authors:  A Bersano; A Aghemo; M G Rumi; E Ballabio; L Candelise; M Colombo
Journal:  Eur J Intern Med       Date:  2007-11-28       Impact factor: 4.487

View more
  216 in total

1.  Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior.

Authors:  Elisabeth G Vichaya; Phillip S Gross; Darlene J Estrada; Steve W Cole; Aaron J Grossberg; Scott E Evans; Michael J Tuvim; Burton F Dickey; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2019-02-26       Impact factor: 4.530

Review 2.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

Review 3.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

4.  Neurotherapeutic implications of brain-immune interactions.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2014-01       Impact factor: 7.853

5.  Inflammation and depressive phenotypes: evidence from medical records from over 12 000 patients and brain morphology.

Authors:  Maria Ironside; Roee Admon; Stephanie A Maddox; Malavika Mehta; Samuel Douglas; David P Olson; Diego A Pizzagalli
Journal:  Psychol Med       Date:  2019-10-16       Impact factor: 7.723

6.  COVID-19 and Involvement of the Corpus Callosum: Potential Effect of the Cytokine Storm?

Authors:  C Rasmussen; I Niculescu; S Patel; A Krishnan
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-30       Impact factor: 3.825

7.  Higher Peripheral Inflammatory Signaling Associated With Lower Resting-State Functional Brain Connectivity in Emotion Regulation and Central Executive Networks.

Authors:  Robin Nusslock; Gene H Brody; Casey C Armstrong; Ann L Carroll; Lawrence H Sweet; Tianyi Yu; Allen W Barton; Emily S Hallowell; Edith Chen; James P Higgins; Todd B Parrish; Lei Wang; Gregory E Miller
Journal:  Biol Psychiatry       Date:  2019-05-01       Impact factor: 13.382

Review 8.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

Review 9.  The organization of the stress system and its dysregulation in depressive illness.

Authors:  P W Gold
Journal:  Mol Psychiatry       Date:  2014-12-09       Impact factor: 15.992

10.  Expression analysis of GRIN2B, BDNF, and IL-1β genes in the whole blood of epileptic patients.

Authors:  Anoushe Zhand; Arezou Sayad; Soudeh Ghafouri-Fard; Shahram Arsang-Jang; Mehrdokht Mazdeh; Mohammad Taheri
Journal:  Neurol Sci       Date:  2018-08-23       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.